Propensity score matching analysis of the effect of the Yiqi Yangjing Prescription on the survival prognosis of patients with stage Ⅰ⁃ⅢA lung adenocarcinoma after surgery

WANG Yuhan; DONG Yun; YANG Yi; CUI Qing; CAI Xiaoyue; ZHOU Yaning; ZHANG Shi; ZHANG Ming

doi:10.16305/j.1007-1334.2023.2301003

您当前的位置：

首页 >

文章列表页 >

Propensity score matching analysis of the effect of the Yiqi Yangjing Prescription on the survival prognosis of patients with stage Ⅰ⁃ⅢA lung adenocarcinoma after surgery

更新时间：2023-06-16

- Propensity score matching analysis of the effect of the Yiqi Yangjing Prescription on the survival prognosis of patients with stage Ⅰ⁃ⅢA lung adenocarcinoma after surgery
- Shanghai Journal of Traditional Chinese Medicine Vol. 57, Issue 6, Pages: 50-55(2023)
- 作者机构：
  
  1.上海交通大学医学院附属胸科医院中西医结合科（上海 200030）
  2.上海交通大学医学院附属胸科医院肿瘤科（上海 200030）
- 作者简介：
- 基金信息：
- DOI：10.16305/j.1007-1334.2023.2301003
  CLC：
扫描看全文
汪宇涵,董昀,杨轶,等.运用倾向性评分匹配分析益气养精方对Ⅰ～ⅢA期肺腺癌术后患者生存预后的影响[J].上海中医药杂志,2023,57(6):50-55.

WANG Yuhan,DONG Yun,YANG Yi,et al.Propensity score matching analysis of the effect of the Yiqi Yangjing Prescription on the survival prognosis of patients with stage Ⅰ⁃ⅢA lung adenocarcinoma after surgery[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(6):50-55.
汪宇涵,董昀,杨轶,等.运用倾向性评分匹配分析益气养精方对Ⅰ～ⅢA期肺腺癌术后患者生存预后的影响[J].上海中医药杂志,2023,57(6):50-55. DOI： 10.16305/j.1007-1334.2023.2301003.

WANG Yuhan,DONG Yun,YANG Yi,et al.Propensity score matching analysis of the effect of the Yiqi Yangjing Prescription on the survival prognosis of patients with stage Ⅰ⁃ⅢA lung adenocarcinoma after surgery[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(6):50-55. DOI： 10.16305/j.1007-1334.2023.2301003.

摘要

目的,2,探析益气养精方对Ⅰ～ⅢA期肺腺癌根治术后患者生存预后的影响。,方法,2,以2012年1月1日至2015年12月31日上海交通大学医学院附属胸科医院中西医结合科收治的Ⅰ～ⅢA期肺腺癌根治术后患者为研究对象，根据是否接受过益气养精方为主的中药治疗，分为中药组和对照组；采用倾向性评分匹配（PSM）平衡组间混杂因素，Kaplan-Meier法分析比较两组总生存期（OS）和无病生存期（DFS），Cox回归模型分析预后风险因素。,结果,2,①共纳入357例Ⅰ～ⅢA期肺腺癌根治术后患者，按1∶1进行PSM后，成功匹配204例，中药组和对照组均为102例。②PSM前，中药组5年OS率高于对照组（79.7% vs 64.2%，,P,=0.001），且5年DFS率较对照组更高（60.6% vs 47.2%，,P,=0.005）；PSM后，中药组5年OS率高于对照组（68.6% vs 52.5%，,P,=0.038），5年DFS率较对照组高但差异无统计学意义（49.0% vs 43.1%，,P,=0.176）。③PSM后的Cox单因素分析显示，组织学亚型是否含有高危病理因素（,P,=0.009）和是否服用中药（,P,=0.046）与OS显著相关；组织学亚型是否含有高危病理因素（,P,=0.031）和TNM分期（,P,=0.002）与DFS显著相关。④Cox多因素分析显示，是否含有高危病理因素（,P,=0.002）和是否服用中药（,P,=0.030）是影响Ⅰ～ⅢA期肺腺癌根治术后患者OS的独立预后因素；而是否含有高危病理因素（,P,=0.027）和临床TNM分期（,P,=0.001）是影响Ⅰ～ⅢA期肺腺癌根治术后患者DFS的独立预后因素。,结论,2,Ⅰ～ⅢA期肺腺癌根治术后尤其是组织学亚型有高危病理因素的患者，在西医治疗基础上服用益气养精方为主的中药，可达到延长生存期的治疗效果。

Abstract

Objective,2,To retrospectively analyze the effect of the Yiqi Yangjing （benefiting qi and nourishing essence） Prescription on the survival prognosis of patients with stage Ⅰ-ⅢA lung adenocarcinoma after radical surgery.,Methods,2,We included patients with stage Ⅰ-ⅢA non-small cell lung adenocarcinoma after radical surgery who were admitted to the Department of Integrative Medicine， Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from January 1， 2012 to December 31， 2015， and these study subjects were divided into traditional Chinese medicine （TCM） and control groups depending on whether they had received Yiqi Yangjing Prescription-based TCM treatment. The propensity score matching （PSM） was used to exclude the confounding factors and bias， the Kaplan-Meier method was used to compare the overall survival （OS） and disease-free survival （DFS） between the two groups， and the Cox Proportional-Hazards Model was used to analyze the prognostic risk factors.,Results,2,①A total of 357 patients with stage Ⅰ-ⅢA lung adenocarcinoma after radical surgery were included. After conducting a 1∶1 propensity score matching procedure， we got 204 successfully matched cases， with 102 cases in each group. ②Before PSM analysis， the 5-year OS rate was higher in the TCM group than that in the control group （79.7% vs. 64.2%， ,P,=0.001）， and the 5-year DFS rate was higher than that in the control group （60.6% vs. 47.2%， ,P,=0.005）； after PSM analysis， the 5-year OS rate was higher in the TCM group than that in the control group （68.6% vs. 52.5%， ,P,=0.038）， and the 5-year DFS rate was higher than that in the control group， but the difference was not statistically significant （49.0% vs 43.1%， ,P,=0.176）. ③The Cox univariate analysis after PSM showed that the presence of high-risk pathological factors in histological subtypes （,P,=0.009） and the administration of TCM （,P,=0.046） were significantly associated with OS； and the presence of high-risk pathological factors in histological subtypes （,P,=0.031） and TNM stage （,P,=0.002） were significantly associated with DFS. ④The Cox multifactorial analysis showed that the presence of high-risk pathological factors （,P,=0.002） and the administration of TCM （,P,=0.030） were independent prognostic factors affecting OS in patients with stage Ⅰ-ⅢA lung adenocarcinoma after radical surgery； while the presence of high-risk pathological factors （,P,=0.027） and clinical TNM stage （,P,=0.001） were independent prognostic factors affecting DFS in patients with stage Ⅰ-ⅢA lung adenocarcinoma after radical surgery.,Conclusion,2,The treatment effect of prolonging survival can be achieved by using Yiqi Yangjing Prescription-based TCM treatment in addition to Western medicine conventional treatment in patients with stage Ⅰ-ⅢA lung adenocarcinoma after radical surgery， especially those with high-risk pathological factors in histological subtypes.

关键词

非小细胞肺癌中医药疗法倾向性评分匹配生存期预后

Keywords

non-small cell lung cancertraditional Chinese medicine therapypropensity score matching （PSM）survival periodprognosis

references

SCHOORS S， DE BOCK K， CANTELMO A R， et al. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis［J］. Cell Metab， 2014， 19（1）： 37-48.

KAZEROONI E A， ARMSTRONG M R， AMOROSA J K， et al. ACR CT accreditation program and the lung cancer screening program designation［J］. J Am Coll Radiol， 2016， 13（2 Suppl）： 30-34.

TSAO M S， MARGUET S， LE TEUFF G， et al. Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection［J］. J Clin Oncol， 2015， 33（30）： 3439-3446.

SUEHISA H， TOYOOKA S. Adjuvant chemotherapy for completely resected non-small-cell lung cancer［J］. Acta Med Okayama， 2009， 63（5）： 223-230．

ZHU C Q， DING K， STRUMPF D， et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer［J］. J Clin Oncol， 2010， 28（29）： 4417-4424.

TRAVIS W D， BRAMBILLA E， NOGUCHI M， et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma［J］. J Thorac Oncol， 2011， 6（2）： 244-285.

CHA M J， LEE H Y， LEE K S， et al. Micropapillary and solid subtypes of invasive lung adenocarcinoma： clinical predictors of histopathology and outcome［J］. J Thorac Cardiovasc Surg， 2014， 147（3）： 921-928.

SUMIYOSHI S， YOSHIZAWA A， SONOBE M， et al. Pulmonary adenocarcinomas with micropapillary component significantly correlate with recurrence， but can be well controlled with EGFR tyrosine kinase inhibitors in the early stages［J］. Lung Cancer， 2013， 81（1）： 53-59.

UJIIE H， KADOTA K， CHAFT J E， et al. Solid predominant histologic subtype in resected stage Ⅰ lung adenocarcinoma is an independent predictor of early， extrathoracic， multisite recurrence and of poor postrecurrence survival［J］. J Clin Oncol， 2015， 33（26）： 2877-2884.

YANAGAWA N， SHIONO S， ABIKO M， et al. The correlation of the International Association for the Study of Lung Cancer （IASLC）/American Thoracic Society （ATS）/European Respiratory Society （ERS） classification with prognosis and EGFR mutation in lung adenocarcinoma［J］. Ann Thorac Surg， 2014， 98（2）： 453-458.

WARTH A， MULEY T， MEISTER M， et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival［J］. J Clin Oncol， 2012， 30（13）： 1438-1446.

RUSSELL P A， WAINER Z， WRIGHT G M， et al. Does lung adenocarcinoma subtype predict patient survival？： A clinicopath-ologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification［J］. J Thorac Oncol， 2011， 6（9）： 1496-1504.

KRIS M G， GASPAR L E， CHAFT J E， et al．Adjuvant systemic therapy and adjuvant radiation therapy for stage Ⅰ to ⅢA completely resected non-small-cell lung cancers： American society of clinical oncology/cancer care ontario clinical practice guideline update［J］. J Clin Oncol，2017， 35（25）： 2960-2974．

PIGNON J P， TRIBODET H， SCAGLIOTTI G V， et al. Lung adjuvant cisplatin evaluation： a pooled analysis by the LACE Collaborative Group［J］. J Clin Oncol， 2008， 26（21）： 3552-3559．

张铭，董昀，徐振晔，等. 肺岩宁方对A549裸鼠移植瘤VEGF与HIF-1α表达的影响［J］.上海中医药杂志，2008， 42（5）： 83-85.

徐振晔，金长娟，沈德义，等. 中医药分阶段结合化疗治疗晚期非小细胞肺癌的临床研究［J］. 中国中西医结合杂志，2007， 27（10）： 874-878.

ETTINGER D S， WOOD D E， AISNER D L. Non-small cell lung cancer， version 3.2022， NCCN clinical practice guidelines in oncology［J］. J Natl Compr Canc Netw， 2022， 20 （5）： 497-530.

GOLDSTRAW P， CHANSKY K， CROWLEY J， et al. The IASLC lung cancer staging project： proposals for the revision of the stage grouping in the forthcoming （8th） edition of the TNM classification of lung cancer［J］. J Thorac Oncol， 2016， 11（1）： 39-51.

HUNG J J， JENG W J， CHOU T Y， et al. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma［J］. Ann Surg， 2013， 258 （6）： 1079-1086.

LUO J， HUANG Q， WANG R， et al. Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage I B［J］. J Cancer Res Clin Oncol， 2016， 142 （9）： 2031-2040.

张铭，徐振晔，白冰，等. 肺岩宁方下调裸鼠人肺腺癌细胞移植瘤中磷酸化Akt和缺氧诱导因子1α蛋白表达［J］. 中西医结合学报，2008， 6（6）： 616-620.

汪宇涵，张铭，崔清，等. 益气养精方对人肺癌A549细胞糖酵解通路中HIF-1α和PFKFB3蛋白的调节作用［J］. 中华中医药学刊，2019， 37（9）： 2155-2158.

XU Z Y， JIN C J， ZHOU C C， et al. Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy［J］. J Cancer Res Clin Oncol， 2011， 137（7）： 1117-1122.

GONG Y， XU Z， JIN C， et al. Treatment of advanced non-small-cell lung cancer with qi-nourishing essence-replenishing Chinese herbal medicine combined with chemotherapy［J］. Biol Proced Online， 2018， 20： 9.

Views

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of traditional Chinese medicine syndrome differentiation and treatment combined with Icotinib on survival of elderly patients with EGFR-mutant advanced lung adenocarcinoma

Staged rehabilitation treatment strategy of traditional Chinese medicine after non⁃small cell lung cancer surgery

Efficacy and safety of Yiqi Yangyin Jiedu regimen plus anlotinib in the treatment of advanced non⁃small cell lung cancer

Clinical analysis of PD-1 monoclonal antibody supplemented with traditional Chinese medicine in the treatment of non-small cell lung cancer

Effects of Chaihu Shugan Powder on AMPK/SIRT3 signaling pathway in rats with functional dyspepsia

Related Author

No data

Related Institution

The 6th Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Respiratory Department, Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University

Department of Oncology I， Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

Institute of Clinical Immunology， Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

⁰